Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.32 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.32 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869468 | 0.90 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1GPR84 | |
| SCHEMBL21310427 | 0.90 | OPRM1 (0.33) | OPRM1OPRD1OPRK1OPRL1GPR84 | |
| SCHEMBL24555526 | 0.89 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL19275191 | 0.89 | OPRM1 (0.38) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL24486062 | 0.85 | FDPS (0.36) | OPRM1GPR84FDPSFFAR1LMNA | |
| SCHEMBL25516925 | 0.85 | FDPS (0.36) | OPRM1GPR84FDPSFFAR1LMNA | |
| SCHEMBL25518417 | 0.85 | FDPS (0.36) | OPRM1GPR84FDPSFFAR1LMNA | |
| SCHEMBL22446841 | 0.83 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OPRL1GPR84 | |
| SCHEMBL22962165 | 0.83 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1FDPS | |
| SCHEMBL22962175 | 0.83 | OPRM1 (0.36) | OPRM1OPRD1OPRK1OPRL1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | OPRM1 4820/4885OPRD1 3859/4885OPRK1 4508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.